BLUE BELL, Pa., Dec. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, has been invited to participate on an expert panel titled, Ovarian & Cervical Cancer – Evaluating the Role of Immunotherapy Exploring Three Approaches – Dendritic Cells, DNA Plasmids & Liposomal Delivery. Dr. Kim will discuss Inovio's DNA immunotherapy VGX-3100, which was designed to treat cervical pre-cancers and cancers, head & neck cancers, and anogenital cancers caused by human papillomavirus (HPV). Moderated by Maxim Group Managing Director and Senior Biotechnology Analyst, Jason Kolbert, and sponsored by ProActive Capital Group, this webinar will take place on Wednesday, December 11, at 4:00 pm ET. Access to this panel discussion can be obtained through the following link: http://bit.ly/1f5r6vTAbout Cervical Cancer Cervical cancer is the most commonly occurring cancer among women in developing countries and is the second most commonly occurring cancer amongst women worldwide. Cervical cancer currently affects 530,000 women worldwide and results in 288,000 deaths annually. According to the World Health Organization, cervical cancer is 100% attributable to human papilloma virus (HPV). Preventive vaccines such as GARDASIL® and CERVARIX® are playing an important role in limiting new HPV infections but cannot protect those already infected by HPV, which is present in an estimated 10% of the global population. In addition, a significant number of girls and women eligible for vaccination are not receiving these preventive vaccines. There is no viable therapeutic vaccine or drug to treat HPV, nor the pre-cancers and cancers caused by HPV. About VGX-3100 VGX-3100, designed to treat HPV-caused cancers and pre-cancers, has completed enrollment of a phase II trial for late stage cervical dysplasia (CIN 2/3), with efficacy data to be reported mid-year 2014. Inovio plans to enter human phase I/IIa trials next year for HPV-caused cervical and head & neck cancers, the latter the most rapidly growing cancer in men. VGX-3100 is designed to raise immune responses against the E6 and E7 oncogenes associated with HPV types 16 and 18. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The goal is to stimulate a T-cell immune response strong enough to cause the rejection of these infected or transformed cells from the body. VGX-3100 was recognized as the most promising research at the 2011 Global Vaccine Congress, winning first prize in the Edward Jenner Award Competition; it was also recognized by the Vaccine Industry Excellence Awards for "Best Therapeutic Vaccine" in 2013. Best-in-class T cell data from our phase I study was highlighted in a paper published in Science Translational Medicine. About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com. This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. CONTACTS:Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 email@example.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, firstname.lastname@example.org (Logo: http://photos.prnewswire.com/prnh/20131118/LA18202LOGO) SOURCE Inovio Pharmaceuticals, Inc.